One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: The multicentre PROMUS element European post-approval surveillance study

EuroIntervention

Volumn 10, Issue 11, 2015, Pages 1267-1271

  Thomas, Martyn R ^a   Birkemeyer, Ralf ^b   Schwimmbeck, Peter ^c   Legrand, Victor ^d   Moreno, Raul ^e   Briguori, Carlo ^f   Werner, Nikos ^g   Bramucci, Ezio ^h   Ungi, Imre ⁱ   Richardt, Gert ^j   Underwood, Paul L ^k   Dawkins, Keith D ^k  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c KLINIKUM LEVERKUSEN   (Germany)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f Clinica Mediterranea   (Italy)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ UNIVERSITY OF SZEGED   (Hungary)

^j Segeberger Kliniken GmbH   (Germany)

^k BOSTON SCIENTIFIC CORPORATION   (United States)

more..

Author keywords

Coronary stenosis; Drug eluting stents; Everolimus; Observational study

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PRASUGREL; TICAGRELOR; ANTINEOPLASTIC AGENT;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULATION; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; EUROPE; EVEROLIMUS ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASE; CORONARY STENOSIS; DEVICES; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTMARKETING SURVEILLANCE; REOPERATION; UTILIZATION;

AGED; ANGINA, UNSTABLE; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY STENOSIS; DRUG-ELUTING STENTS; EUROPE; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; PRODUCT SURVEILLANCE, POSTMARKETING; REOPERATION;

EID: 84927602080     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M01_07     Document Type: Article

References (12)

1. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-8.
2. Meredith IT, Teirstein PS, Bouchard A, Carrie D, Mollmann H, Oldroyd KG, Hall J, Allocco DJ, Dawkins KD, Stone GW. Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial). Am J Cardiol. 2014;113:1117-23.
3. De la Torre Hernandez JM, Garcia Camarero T, Lerena P, Lee DH, Sainz Laso F, Gorria GM, Zueco J. A real all-comers randomized trial comparing Xience Prime and Promus Element stents. J Invasive Cardiol. 2013;25:182-5.
4. Sarno G, Lagerqvist B, Carlsson J, Olivecrona G, Nilsson J, Calais F, Gotberg M, Nilsson T, Sjogren I, James S. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Int J Cardiol. 2013;167:146-50.
5. Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB. A new era of prospective real-world safety evaluation: Primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc Interv. 2011;4:1298-309.
6. Damman P, Abdel-Wahab M, Mollmann H, Richardt G, Chevalier B, Barragan P, Tijssen JG, Underwood P, Hamm CW. Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry. J Invasive Cardiol. 2012;24:495-502.
7. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-9.
8. Neumann FJ, Widimsky P, Belardi JA. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. EuroIntervention. 2012;7:1181-8.
9. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377:1241-7.
10. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der Palen J, Verhorst PM, de Man FH. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in realworld patients: the TWENTE trial. J Am Coll Cardiol. 2012;59: 1350-61.
11. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569-77.
12. The GUSTO Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673-82.